Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan. It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic. The company was founded in 2011 an… Read more
Market Cap & Net Worth: Original BioMedicals Co., Ltd. (6483)
Original BioMedicals Co., Ltd. (TWO:6483) has a market capitalization of $32.89 Million (NT$1.09 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #24253 globally and #1462 in its home market, demonstrating a -2.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Original BioMedicals Co., Ltd.'s stock price NT$16.40 by its total outstanding shares 66351000 (66.35 Million).
Original BioMedicals Co., Ltd. Market Cap History: 2026 to 2026
Original BioMedicals Co., Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $32.89 Million to $32.89 Million (0.00% CAGR).
Original BioMedicals Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Original BioMedicals Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6483 by Market Capitalization
Companies near Original BioMedicals Co., Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Original BioMedicals Co., Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Original BioMedicals Co., Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Original BioMedicals Co., Ltd.'s market cap moved from $32.89 Million to $ 32.89 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$32.89 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Original BioMedicals Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.89 Million USD |
| MoneyControl | $32.89 Million USD |
| MarketWatch | $32.89 Million USD |
| marketcap.company | $32.89 Million USD |
| Reuters | $32.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.